We have continued to execute on our key corporate objectives by filing the U.S. Vitaros NDA resubmission with the FDA and improving our financial outlook, resulting in a balance sheet that is expected to fund our current operating plan through the end of 2018.
Importantly, the FDA acknowledged receipt of our resubmission and our PDUFA goal date is February 17, 2018. For the remainder of 2017, we will focus on working with the FDA regarding the Vitaros NDA, maintaining a productive dialogue with Allergan regarding the commercial potential for Vitaros in the United States, securing a development partner for RayVa, and continuing to diligently manage our corporate resources.
Thank you again for your continued support of Apricus as we look forward to a strong finish in 2017.
Richard W. Pascoe
Chief Executive Officer